Atossa reports preliminary cash balance of ~$40M, limited other details

ATOSSA THERAPEUTICS, INC.

Estimated cash and cash equivalents of ~$40M as of Dec 31, 2025, preliminary and unaudited.
No quarterly earnings, revenue, or operational results were disclosed in this filing.
Updated corporate presentation likely focuses on (Z)-Endoxifen development strategy per forward-looking statements.
Cash estimate subject to finalization of year-end financial closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.